This suggests that either Notch2 or Notch3 inhibition can have therapeutic activity in SCLC cells or that non-cell autonomous effects on tumor stroma mediated by Notch2/3 inhibition are responsible for this effect. This evidence concerns the gene NOTCH2 and small cell lung carcinoma.